MedTrace Logo

Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile

NCT02949752 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2021-07-21

No results posted yet for this study

Summary

This is an open label study to prospectively evaluate the effect of adjunct use of Aripiprazole, as an agent to improve metabolic profile and induce weight loss in patients established on atypical antipsychotics (Olanzapine, Clozapine and Risperidone).

Conditions

  • Antipsychotics Weight Gain

Interventions

DRUG

Aripiprazole

Aripiprazole 5 mg every morning will be prescribed for 12 weeks

Sponsors & Collaborators

  • Institute of Mental Health, Singapore

    lead OTHER

Principal Investigators

  • Bhanu Gupta, MRCPsych · Institute of Mental Health, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-10-01
Completion
2020-01-01

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02949752 on ClinicalTrials.gov